Skip to content

Study · In vitro (cells) · 1990

6 results

Thymosin alpha 1 modulates the expression of high affinity interleukin-2 receptors on normal human lymphocytes.

Leichtling KD, Serrate SA, Sztein MB

International journal of immunopharmacology1 Jan 1990Cited by 59 (Europe PMC)

PMID2303316 (opens in a new tab)DOI10.1016/0192-0561(90)90064-t (opens in a new tab)PepBankPUB-02303316
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In PHA-stimulated human peripheral blood lymphocytes, thymosin alpha‑1 increased the number of high affinity interleukin 2 receptors.

    In plain wordsIn lab tests on human white blood cells, thymosin alpha‑1 raised the number of high affinity IL-2 receptors.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseHigh affinity IL-2 receptor number
    Study

    humann: not reported in source

    peripheral blood lymphocytes stimulated with PHA
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    thymosin alpha 1 (T alpha 1), a synthetic peptide composed of 28 amino acid residues, and thymosin fraction 5 (TF5) enhance the number of high affinity interleukin 2 receptors (IL-2R) expressed by human peripheral blood lymphocytes in response to in vitro stimulation with phytohemagglutinin (PHA).
  2. 02LabIn vitro (cells)Activity measurement

    In PHA-stimulated human lymphocytes, thymosin alpha‑1 did not change the affinity of the IL-2 receptor for its ligand.

    In plain wordsIn lab tests on human white blood cells, thymosin alpha‑1 did not change how tightly IL-2 receptors bind IL-2.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeIL-2 receptor affinity for its ligand
    Study

    humann: not reported in source

    peripheral blood lymphocytes stimulated with PHA
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Thymosins did not, however, alter the affinity of the IL-2R for its ligand.
  3. 03LabIn vitro (cells)Activity measurement

    In human lymphocytes, the response to thymosin alpha‑1 was bimodal, with peaks of activity at 10(-8) M and 10(-12) M in most experiments.

    In plain wordsIn lab tests on human white blood cells, thymosin alpha‑1 showed two concentration peaks of activity, a high and a low one.

    Peptide
    Thymosin alpha-1
    Outcome
    MixedDose-response of IL-2 receptor expression
    Study

    humann: not reported in source

    peripheral blood lymphocytes stimulated with PHA
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Dose-response studies using a wide range of concentrations indicated a bimodal distribution of responsiveness to T alpha 1. In most experiments the high and low concentration peaks of activity were observed at 10(-8) M and 10(-12) M, respectively, although peak responses were observed at different T…
  4. 04LabIn vitro (cells)Activity measurement

    In human lymphocytes, thymosins had no effect without mitogenic stimulation.

    In plain wordsIn lab tests on human white blood cells, thymosins had no effect unless the cells were also stimulated.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeThymosin effect without mitogenic stimulation
    Study

    humann: not reported in source

    peripheral blood lymphocytes stimulated with PHA
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No effects were elicited by thymosins in the absence of mitogenic stimulation.
  5. 05LabIn vitro (cells)Activity measurement

    In PHA-stimulated human lymphocytes, thymosin enhancement of high affinity IL-2 receptor expression correlated with increased Tac antigen expression.

    In plain wordsIn lab tests on human white blood cells, thymosin raised Tac antigen levels, in step with high affinity IL-2 receptors.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseTac antigen expression
    Study

    humann: not reported in source

    peripheral blood lymphocytes stimulated with PHA
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Thymosin enhancement of PHA-induced high affinity IL-2R expression directly correlated with increased levels of Tac antigen expression, as determined by flow cytometry
  6. 06LabIn vitro (cells)Activity measurement

    In PHA-stimulated human lymphocytes, thymosin enhanced interleukin 2 production.

    In plain wordsIn lab tests on human white blood cells, thymosin raised IL-2 production.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseIL-2 production
    Study

    humann: not reported in source

    peripheral blood lymphocytes stimulated with PHA
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    enhanced interleukin 2 (IL-2) production.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.